Pharmaceutical policies in the long run:
reflections on the 60th anniversary of the Hinchliffe Report
History - sustainability of pharmaceutical expenditure then and now
Today’s challenges: pricing decisions and opportunity cost
Mr Danny Palnoch, Head of Medicines Analysis, Strategy and Policy, NHS England
NHS drug costs: how does the most recent decade compare with the first?
Dr Elaine Kelly, Senior Research Economist, Institute for Fiscal Studies and the Health
“Restriction on quantitites”: the problem of drug shortages
Dr Jeffrey Aronson, Consultant Physician and Clinical Pharmacologist, Nuffield Department of Primary Health Care Sciences
Generating and reporting of evidence
Clinical trials in the NHS – how did we do?
Professor Louise Bowman, Professor of Medicine and Clinical Trials, Nuffield Department of Population Health
Clinical trials in the NHS – how can we do more?
Professor Martin Landray, Nuffield Department of Population Health
Training of medical practitioners & use of evidence based medicine
Back to medical school – what I wish I’d learned about health economics
Dr Amanda Adler, Chair of NICE Appraisal Committee and Consultant Physician
Economics of drug development & marketing
The Hinchliffe Report: cost control and the prescription charge
Professor Darrin Baines, Professor in Health Economics,, Bournemouth University
Costs of R&D and reflections on marketing
Professor Adrian Towse, Office for Health Economics
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to the NHS
Dr Beth Woods, Senior Research Fellow, Centre for Health Economics, University of York
NICE re-imagined
Professor Philip Clarke, Health Economics Research Centre, Nuffield Department of Population Health
Closing remarks
Professor Sir Rory Collins, Nuffield Department of Population Health